Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 3, 1997, Pages 1001-1008

  Bottone, Antonio E ^a   De Beer, Evert L ^a   Voest, Emile E ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anthracycline; Cardiomyopathy; Doxorubicin; Isometric tension; Muscle

Indexed keywords

ACTIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; MYOSIN; PACLITAXEL;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE TENSION; INOTROPISM; MALE; MUSCLE FORCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0031104952     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0345     Document Type: Article

References (37)

1. ARCAMONE F, 1985. Properties of antitumour anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res 45: 5995-5999.
2. AZUMA J, SPERELAKIS N, HASEGAWA H, TANIMOTO T, VOGEL S, OGURA K, AWATA N, SAWAMURA A, HARADA H, ISHIYAMA T, MORITA Y, YAMAMURA Y, 1981. Adriamycin cardiotoxicity: possible pathogenic mechanisms. J Mol Cell Cardiol 13: 381-397.
3. BROWN KA, BLOW AJ, WEISS RM, STEWART JA, 1989. Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J 118: 979-982.
4. CERSOSIMO RJ, 1992. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 11: 152-167.
5. DE BEER EL, FINKLE H, VOEST EE, VAN HEIJST BGV, SCHIERECK P, 1992. Doxorubicin interacts directly with skinned single skeletal muscle fibers. Eur J Pharmacol 214: 97-100.
6. DE WINKEL ME, BLANGE T, TREIJTEL BW, 1995. Viscoelastic properties of cross bridges in cardiac muscle. Am J Physiol 268: H987-H998.
7. DOROSHOW JH, 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472.
8. DOROSHOW JH, 1991. Doxorubicin-induced cardiac toxicity. N Engl J Med 324: 843-845.
9. DOROSHOW JH, TALLENT C, SCHECHTER JE, 1985. Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. Am J Pathol 118: 288-297.
10. FABIATO A, FABIATO F, 1978. Effects of pH on myofibrils and sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J Physiol (Lond) 276: 233-256.
11. GILLADOGA AC, MANUEL C, TAN CT, WOLLNER N, STERNBERG SS, MURPHY ML, 1976. The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37: 1070-1078.
12. HARRISON SM, LAMONT C, MILLER DJ, 1988. Hysteresis and the length dependence of calcium sensitivity in chemically skinned rat cardiac muscle. J Physiol (Lond) 401: 115-143.
13. 2+-sensitivity of rat, guinea pig and frog ventricular muscle. Am J Physiol 258: C241-C281.
14. HOFLING B, BOLTE HD, 1981. Acute negative inotropic effect of adriamycin (doxorubicin). Naunyn-Schmied Arch Pharmacol 317: 252-256.
15. HOLMBERG SRM, WILLIAMS AJ, 1990. Patterns of interaction between anthraquinone drugs and the adriamycin-release channel from cardiac sarcoplasmic reticulum. Circ Res 67: 272-283.
16. JAENKE RS, DEPREZ-DECAMPENEERE D, TROUET A, 1980. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res 40: 3530-3536.
17. JAIN KK, CASPER ES, GELLER NL, HAKES TB, KAUFMAN RJ, CURRIE V, SCHWARTZ W, CASSIDY C, PETRONI GR, YOUNG CW, WITTES RE, 1985. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818-826.
18. KAWAI M, BRANDT PW, 1976. Two rigor states in skinned crayfish single muscle fibres. J Gen Physiol 68: 267-280.
19. KENTISH JC, 1984. The inhibitory effects of monovalent ions on force development in detergent-skinned ventricular muscle from guinea pig. J Physiol (Lond) 352: 353-374.
20. KENTISH JC, 1986. The effects of inorganic phosphate and creatine phosphate on force production in skinned muscles from rat ventricle. J Physiol (Lond) 370: 585-604.
21. 2+-regulated force production in EGTA-treated muscle from rat heart. J Gen Physiol 84: 83-99.
22. +-adenosine triphosphatase. J Pharmacol Exp Ther 214: 368-374.
23. MULIERI LA, HASENFUSS G, ITTLEMAN F, BLANCHARD EM, ALPERT NR, 1989. Protection of human left ventricular myocardium from cutting injury with 2,3 butanedione monoxime. Circ Res 65: 1441-1444.
24. OLSON RD, MUSHLIN PS, BRENNER DE, FLEISCHER S, CUSACK BJ, CHANG BK, BOUCEK RJ JR, 1988. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85: 3585-3589.
25. 2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37: 503-514.
26. POLITI PM, ROTHLIN RP, PINTO JEB, 1985. Acute effects of doxorubicin on chronotropic and inotropic mechanisms in guinea pig atria. Cancer Treat Rep 69: 859-865.
27. RABKIN SW, 1983. Interaction of external calcium concentration and verapamil on the effects of doxorubicin (adriamycin) in the isolated heart preparation. J Cardiovasc Pharmacol 5: 848-855.
28. RABKIN SW, OTTEN M, POLIMENI PI, 1983. Increased mortality with cardiotoxic doses of Adriamycin after verapamil pretreatment despite prevention of myocardial calcium accumulation. Can J Physiol Pharmacol 61: 1050-1056.
29. RABKIN SW, GODIN DV, 1985. Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination. Can J Cardiol 1: 4-7.
30. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250: H419-H425.
31. SINGAL PK, DEALLY CMR, WEINBER LE, 1987. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19: 817-828.
32. STIENEN GJM, ROOSEMALEN MCM, WILSON MGA, ELZINGA G, 1990. Depression of force by phosphate in skinned skeletal muscle fibres of the frog. Am J Physiol 259: C349-C357.
33. TEMMA K, AKERA T, CHUGUN A, OHASHI M, YABUKI M, KONDO H, 1992. Doxorubicin: an antagonist of muscarinic receptors in guinea pig heart. Eur J Pharmacol 220: 63-69.
34. UNVERFERTH DV, MAGORIEN RD, UNVERFERTH BP, TALLEY RL, BALCERZAK SP, BABA N, 1981. Human myocardial morphological and functional changes in the first 24 h after doxorubicin administration. Canc Treat Rep 65: 1093-1097.
35. VAN BOXTEL CJ, OLSON RD, BOERTH RC, OATES JA, 1978. Doxorubicin: inotropic effects and inhibitory action of ouabain. J Pharmacol Exp Ther 207: 277-283.
36. VOEST EE, VAN ACKER S, VAN DER VIJGH WJF, VAN ASBECK BS, BAST A, 1994. Comparison of different iron chelators as protective agents against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 26: 1179-1185.
37. YOUNG RC, OZOLS RF, MYERS CE, 1981. The anthracycline antineoplastic drugs. N Engl J Med 305: 139-153.